09:02 AM EDT, 08/26/2024 (MT Newswires) -- NRX Pharmaceuticals' ( NRXP ) HOPE Therapeutics subsidiary said Monday it has signed a non-binding agreement for $30 million in debt financing for its first interventional psychiatric clinics using the drug ketamine.

The company also signed a non-binding agreement for $10 million worth of financing for five existing clinics in the western US.

The company said it has been offered enough financing to build a network of clinics in the US, the UK and France that could generate annual revenue of more than $100 million.

Price: 2.0500, Change: -0.04, Percent Change: -1.91